PATENT CLAIM ANALYSIS

Application Number: 16077610
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "392000"]

Abstract:
Provided in the present invention is a pharmaceutical composition containing an imidazoline derivative. In particular, the pharmaceutical composition provided in the present invention contains (S)-4-(3-(4-(2,3-dihydroxypropoxy) phenyl)-4,4-dimethyl-5-carbonyl-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl) benzonitrile and cellulose ether; and the composition has a good stability, dissolution rate and bioavailability.

Claim (Index 12):
A method for treating and/or preventing prostate cancer in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of  claim 1 .

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.53659
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15108335', '12249157', '12993629', '13703120', '12497282']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7216230261605616
- 35 USC 102 Novelty (BERT): 0.5243757069724678
- Combined Prediction Score: 0.7018982942417522
- Mean Citation Score: 233.663942
- Max Citation Score: 250.25468
- Similarity Product: 134.47372554913758

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test